Therapeutic Possibilities in the Autosomal Recessive Limb-Girdle Muscular Dystrophies

Neurotherapeutics

Volumn 5, Issue 4, 2008, Pages 619-626

  Straub, Volker ^a   Bushby, Kate ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

calpain 3; dysferlin; dystroglycan; Limb girdle muscular dystrophy; sarcoglycan

Indexed keywords

ALPHA SARCOGLYCAN; BETA SARCOGLYCAN; CALPAIN 3; CONNECTIN; DELTA SARCOGLYCAN; DYSFERLIN; DYSTROGLYCAN; FUKUTIN RELATED PROTEIN; GLUCOCORTICOID; MANNOSIDASE INHIBITOR; PROTEASOME INHIBITOR; PROTEIN; PROTEIN O MANNOSE BETA 1,2 N ACETYLGLUCOSAMINYLTRANSFERASE; TELETHONIN; TRIPARTITE MOTIF CONTAINING PROTEIN 32; UNCLASSIFIED DRUG;

ARTHRALGIA; ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BETA SARCOGLYCANOPATHY; BODY POSTURE; CALPAINOPATHY; CHEST INFECTION; CONTRACTURE; DELTA SARCOGLYCANOPATHY; DUCHENNE MUSCULAR DYSTROPHY; DYSFERLINOPATHY; GENE MUTATION; HUMAN; HYPOVENTILATION; JOINT MOBILITY; LIMB GIRDLE MUSCULAR DYSTROPHY; MUSCLE ATROPHY; MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; NONHUMAN; PHYSIOTHERAPY; PRIORITY JOURNAL; RESPIRATORY FUNCTION; SCOLIOSIS; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; CALPAIN; DYSTROGLYCANS; HUMANS; MEMBRANE PROTEINS; MUSCLE PROTEINS; MUSCULAR DYSTROPHIES, LIMB-GIRDLE; SARCOGLYCANS;

EID: 53049091443     PISSN: 19337213     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nurt.2008.08.003     Document Type: Article

References (103)

1. Vainzof M., Ayub-Guerrieri D., Onofre P.C., et al. Animal models for genetic neuromuscular diseases. J Mol Neurosci 34 (2008) 241-248
2. Bassett D.I., and Currie P.D. The zebrafish as a model for muscular dystrophy and congenital myopathy. Hum Mol Genet 12 Spec No 2 (2003) R265-R270
3. Guyon J.R., Steffen L.S., Howell M.H., Pusack T.J., Lawrence C., and Kunkel L.M. Modeling human muscle disease in zebrafish. Biochim Biophys Acta 1772 (2007) 205-215
4. Kunkel L.M., Bachrach E., Bennett R.R., Guyon J., and Steffen L. Diagnosis and cell-based therapy for Duchenne muscular dystrophy in humans, mice, and zebrafish. J Hum Genet 51 (2006) 397-406
5. Sampaolesi M., Torrente Y., Innocenzi A., et al. Cell therapy of alpha-sarcoglycan null dystrophic mice through intra-arterial delivery of mesoangioblasts. Science 301 (2003) 487-492
6. Wagner K.R., Fleckenstein J.L., Amato A.A., et al. A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy. Ann Neurol 63 (2008) 543-545
7. Welch E.M., Barton E.R., Zhuo J., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 447 (2007) 87-91
8. Bushby K., and Straub V. Nonmolecular treatment for muscular dystrophies. Curr Opin Neurol 18 (2005) 511-518
9. Cagliani R., Comi G.P., Tancredi L., et al. Primary beta-sarcoglycanopathy manifesting as recurrent exercise-induced myoglobinuria. Neuromuscul Disord 11 (2001) 389-394
10. Mongini T., Doriguzzi C., Bosone I., Chiado-Piat L., Hoffman E.P., and Palmucci L. Alpha-sarcoglycan deficiency featuring exercise intolerance and myoglobinuria. Neuropediatrics 33 (2002) 109-111
11. Walter M.C., Petersen J.A., Stucka R., et al. FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet 41 (2004) e50
12. Bushby K., Muntoni F., Urtizberea A., Hughes R., and Griggs R. Report on the 124th ENMC International Workshop. Treatment of Duchenne muscular dystrophy; defining the gold standards of management in the use of corticosteroids. 2-4 April 2004, Naarden, The Netherlands. Neuromuscul Disord 14 (2004) 526-534
13. Groen E.J., Charlton R., Barresi R., et al. Analysis of the UK diagnostic strategy for limb girdle muscular dystrophy 2A. Brain 130 (2007) 3237-3249
14. Fardeau M., Eymard B., Mignard C., Tome F.M., Richard I., and Beckmann J.S. Chromosome 15-linked limb-girdle muscular dystrophy: clinical phenotypes in Reunion Island and French metropolitan communities. Neuromuscul Disord 6 (1996) 447-453
15. Passos-Bueno M.R., Moreira E.S., Marie S.K., et al. Main clinical features of the three mapped autosomal recessive limb-girdle muscular dystrophies and estimated proportion of each form in 13 Brazilian families. J Med Genet 33 (1996) 97-102
16. Kawai H., Akaike M., Kunishige M., et al. Clinical, pathological, and genetic features of limb-girdle muscular dystrophy type 2A with new calpain 3 gene mutations in seven patients from three Japanese families. Muscle Nerve 21 (1998) 1493-1501
17. Passos-Bueno M.R., Vainzof M., Moreira E.S., and Zatz M. Seven autosomal recessive limb-girdle muscular dystrophies in the Brazilian population: from LGMD2A to LGMD2G. Am J Med Genet 82 (1999) 392-398
18. Pollitt C., Anderson L.V., Pogue R., Davison K., Pyle A., and Bushby K.M. The phenotype of calpainopathy: diagnosis based on a multidisciplinary approach. Neuromuscul Disord 11 (2001) 287-296
19. de Paula F., Vainzof M., Passos-Bueno M.R., et al. Clinical variability in calpainopathy: what makes the difference?. Eur J Hum Genet 10 (2002) 825-832
20. Sáenz A., Leturcq F., Cobo A.M., et al. LGMD2A: genotype-phenotype correlations based on a large mutational survey on the calpain 3 gene. Brain 128 (2005) 732-742
21. Balci B., Aurino S., Haliloglu G., et al. Calpain-3 mutations in Turkey. Eur J Pediatr 165 (2006) 293-298
22. Guglieri M., Magri F., D'Angelo M.G., et al. Clinical, molecular, and protein correlations in a large sample of genetically diagnosed Italian limb girdle muscular dystrophy patients. Hum Mutat (2007)
23. Bartoli M., Roudaut C., Martin S., et al. Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A. Mol Ther 13 (2006) 250-259
24. Fougerousse F., Gonin P., Durand M., Richard I., and Raymackers J.M. Force impairment in calpain 3-deficient mice is not correlated with mechanical disruption. Muscle Nerve 27 (2003) 616-623
25. Kramerova I., Kudryashova E., Tidball J.G., and Spencer M.J. Null mutation of calpain 3 (p94) in mice causes abnormal sarcomere formation in vivo and in vitro. Hum Mol Genet 13 (2004) 1373-1388
26. Tagawa K., Taya C., Hayashi Y., et al. Myopathy phenotype of transgenic mice expressing active site-mutated inactive p94 skeletal muscle-specific calpain, the gene product responsible for limb girdle muscular dystrophy type 2A. Hum Mol Genet 9 (2000) 1393-1402
27. Wenzel K., Geier C., Qadri F., et al. Dysfunction of dysferlin-deficient hearts. J Mol Med 85 (2007) 1203-1214
28. Illarioshkin S.N., Ivanova-Smolenskaya I.A., Greenberg C.R., et al. Identical dysferlin mutation in limb-girdle muscular dystrophy type 2B and distal myopathy. Neurology 55 (2000) 1931-1933
29. Weiler T., Bashir R., Anderson L.V., et al. Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s). Hum Mol Genet 8 (1999) 871-877
30. Argov Z., Sadeh M., Mazor K., et al. Muscular dystrophy due to dysferlin deficiency in Libyan Jews. Clinical and genetic features. Brain 123 Pt 6 (2000) 1229-1237
31. Illa I., Serrano-Munuera C., Gallardo E., et al. Distal anterior compartment myopathy: a dysferlin mutation causing a new muscular dystrophy phenotype. Ann Neurol 49 (2001) 130-134
32. Mahjneh I., Marconi G., Bushby K., Anderson L.V., Tolvanen-Mahjneh H., and Somer H. Dysferlinopathy (LGMD2B): a 23-year follow-up study of 10 patients homozygous for the same frameshifting dysferlin mutations. Neuromuscul Disord 11 (2001) 20-26
33. Zatz M., de Paula F., Starling A., and Vainzof M. The 10 autosomal recessive limb-girdle muscular dystrophies. Neuromuscul Disord 13 (2003) 532-544
34. Diers A., Carl M., Stoltenburg-Didinger G., Vorgerd M., and Spuler S. Painful enlargement of the calf muscles in limb girdle muscular dystrophy type 2B (LGMD2B) with a novel compound heterozygous mutation in DYSF. Neuromuscul Disord 17 (2007) 157-162
35. Bittner R.E., Anderson L.V., Burkhardt E., et al. Dysferlin deletion in SJL mice (SJL-Dysf) defines a natural model for limb girdle muscular dystrophy 2B. Nature genetics 23 (1999) 141-142
36. Luft F.C. Dysferlin, dystrophy, and dilatative cardiomyopathy. J Mol Med 85 (2007) 1157-1159
37. Ho M., Post C.M., Donahue L.R., et al. Disruption of muscle membrane and phenotype divergence in two novel mouse models of dysferlin deficiency. Hum Mol Genet 13 (2004) 1999-2010
38. Straub V., and Bushby K. The childhood limb-girdle muscular dystrophies. Semin Pediatr Neurol 13 (2006) 104-114
39. Meena A.K., Sreenivas D., Sundaram C., et al. Sarcoglycanopathies: a clinico-pathological study. Neurol India 55 (2007) 117-121
40. White S.J., de Willige S.U., Verbove D., et al. Sarcoglycanopathies and the risk of undetected deletion alleles in diagnosis. Hum Mutat 26 (2005) 59
41. Walter M.C., Dekomien G., Schlotter-Weigel B., et al. Respiratory insufficiency as a presenting symptom of LGMD2D in adulthood. Acta Myol 23 (2004) 1-5
42. Politano L., Nigro V., Passamano L., et al. Evaluation of cardiac and respiratory involvement in sarcoglycanopathies. Neuromuscul Disord 11 (2001) 178-185
43. Merlini L., Kaplan J.C., Navarro C., et al. Homogeneous phenotype of the gypsy limb-girdle MD with the gamma-sarcoglycan C283Y mutation. Neurology 54 (2000) 1075-1079
44. Calvo F., Teijeira S., Fernandez J.M., et al. Evaluation of heart involvement in gamma-sarcoglycanopathy (LGMD2C). A study of ten patients. Neuromuscul Disord 10 (2000) 560-566
45. Bonnemann C.G. Disorders of the sarcoglycan complex (sarcoglycanopathies). In: Deymeer F. (Ed). Neuromuscular diseases: from basic mechanisms to clinical management (2000), Karger, Basel 26-43
46. Angelini C., Fanin M., Freda M.P., Duggan D.J., Siciliano G., and Hoffman E.P. The clinical spectrum of sarcoglycanopathies. Neurology 52 (1999) 176-179
47. van der Kooi A.J., de Voogt W.G., Barth P.G., et al. The heart in limb girdle muscular dystrophy. Heart 79 (1998) 73-77
48. Prelle A., Comi G.P., Tancredi L., et al. Sarcoglycan deficiency in a large Italian population of myopathic patients. Acta Neuropathol (Berl) 96 (1998) 509-514
49. Duggan D.J., Gorospe J.R., Fanin M., Hoffman E.P., and Angelini C. Mutations in the sarcoglycan genes in patients with myopathy. N Engl J Med 336 (1997) 618-624
50. Bushby K., Muntoni F., and Bourke J.P. 107th ENMC international workshop: the management of cardiac involvement in muscular dystrophy and myotonic dystrophy. 7th-9th June 2002, Naarden, the Netherlands. Neuromuscul Disord 13 (2003) 166-172
51. th October 2006, Naarden, The Netherlands. Neuromuscul Disord 17 (2007) 423-428
52. Coral-Vazquez R., Cohn R.D., Moore S.A., et al. Disruption of the sarcoglycan-sarcospan complex in vascular smooth muscle: a novel mechanism for cardiomyopathy and muscular dystrophy. Cell 98 (1999) 465-474
53. Duclos F., Straub V., Moore S.A., et al. Progressive muscular dystrophy in alpha-sarcoglycan-deficient mice. J Cell Biol 142 (1998) 1461-1471
54. Durbeej M., Cohn R.D., Hrstka R.F., et al. Disruption of the beta-sarcoglycan gene reveals pathogenetic complexity of limb-girdle muscular dystrophy type 2E. Mol Cell 5 (2000) 141-151
55. Hack A.A., Ly C.T., Jiang F., et al. Gamma-sarcoglycan deficiency leads to muscle membrane defects and apoptosis independent of dystrophin. J Cell Biol 142 (1998) 1279-1287
56. Kobuke K., Piccolo F., Garringer K.W., et al. A common disease-associated missense mutation in alpha-sarcoglycan fails to cause muscular dystrophy in mice. Hum Mol Genet 17 (2008) 1201-1213
57. Bartoli M., Gicquel E., Barrault L., et al. Mannosidase I inhibition rescues the human alpha-sarcoglycan R77C recurrent mutation. Hum Mol Genet 17 (2008) 1214-1221
58. Iwata Y., Katanosaka Y., Shijun Z., et al. Protective effects of Ca2+ handling drugs against abnormal Ca2+ homeostasis and cell damage in myopathic skeletal muscle cells. Biochem Pharmacol 70 (2005) 740-751
59. Iwanaga Y., Gu Y., Dieterle T., et al. A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. Faseb J 18 (2004) 587-588
60. Li J., Wang D., Qian S., Chen Z., Zhu T., and Xiao X. Efficient and long-term intracardiac gene transfer in delta-sarcoglycan-deficiency hamster by adeno-associated virus-2 vectors. Gene Ther 10 (2003) 1807-1813
61. Toyo-oka T., Kawada T., Xi H., et al. Gene therapy prevents disruption of dystrophin-related proteins in a model of hereditary dilated cardiomyopathy in hamsters. Heart, Lung Circ 11 (2002) 174-181
62. Kawada T., Nakazawa M., Nakauchi S., et al. Rescue of hereditary form of dilated cardiomyopathy by rAAV-mediated somatic gene therapy: amelioration of morphological findings, sarcolemmal permeability, cardiac performances, and the prognosis of TO-2 hamsters. Proc Natl Acad Sci U S A 99 (2002) 901-906
63. Kondoh H., Sawa Y., Miyagawa S., et al. Longer preservation of cardiac performance by sheet-shaped myoblast implantation in dilated cardiomyopathic hamsters. Cardiovasc Res 69 (2006) 466-475
64. Pouly J., Hagege A.A., Vilquin J.T., et al. Does the functional efficacy of skeletal myoblast transplantation extend to nonischemic cardiomyopathy?. Circulation 110 (2004) 1626-1631
65. Ohno N., Fedak P.W., Weisel R.D., Mickle D.A., Fujii T., and Li R.K. Transplantation of cryopreserved muscle cells in dilated cardiomyopathy: effects on left ventricular geometry and function. J Thorac Cardiovasc Surg 126 (2003) 1537-1548
66. Serose A., Salmon A., Fiszman M.Y., and Fromes Y. Short-term treatment using insulin-like growth factor-1 (IGF-1) improves life expectancy of the delta-sarcoglycan deficient hamster. J Gene Med 8 (2006) 1048-1055
67. Serose A., Prudhon B., Salmon A., Doyennette M.A., Fiszman M.Y., and Fromes Y. Administration of insulin-like growth factor-1 (IGF-1) improves both structure and function of delta-sarcoglycan deficient cardiac muscle in the hamster. Basic Res Cardiol 100 (2005) 161-170
68. Nakamura T., Matsumoto K., Mizuno S., Sawa Y., and Matsuda H. Hepatocyte growth factor prevents tissue fibrosis, remodeling, and dysfunction in cardiomyopathic hamster hearts. Am J Physiol 288 (2005) H2131-H2139
69. Iwase M., Kanazawa H., Kato Y., et al. Growth hormone-releasing peptide can improve left ventricular dysfunction and attenuate dilation in dilated cardiomyopathic hamsters. Cardiovasc Res 61 (2004) 30-38
70. Gastaldello S., D'Angelo S., Franzoso S., et al. Inhibition of proteasome activity promotes the correct localization of disease-causing alpha-sarcoglycan mutants in HEK-293 cells constitutively expressing beta-, gamma-, and delta-sarcoglycan. Am J Pathol 173 (2008) 170-181
71. Bauer R., Macgowan G.A., Blain A., Bushby K., and Straub V. Steroid treatment causes deterioration of myocardial function in the {delta}-sarcoglycan-deficient mouse model for dilated cardiomyopathy. Cardiovasc Res (2008) Jun 30; [Epub ahead of print]
72. Weller B., Massa R., Karpati G., and Carpenter S. Glucocorticoids and immunosuppressants do not change the prevalence of necrosis and regeneration in mdx skeletal muscles. Muscle Nerve 14 (1991) 771-774
73. Connolly A.M., Pestronk A., Mehta S., and Al-Lozi M. Primary alpha-sarcoglycan deficiency responsive to immunosuppression over three years. Muscle Nerve 21 (1998) 1549-1553
74. Bartoli M., Poupiot J., Vulin A., et al. AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency. Gene Ther 14 (2007) 733-740
75. Bogdanovich S., McNally E.M., and Khurana T.S. Myostatin blockade improves function but not histopathology in a murine model of limb-girdle muscular dystrophy 2C. Muscle Nerve 37 (2008) 308-316
76. Minetti G.C., Colussi C., Adami R., et al. Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitors. Nat Med 12 (2006) 1147-1150
77. Parsons S.A., Millay D.P., Sargent M.A., McNally E.M., and Molkentin J.D. Age-dependent effect of myostatin blockade on disease severity in a murine model of limb-girdle muscular dystrophy. Am J Pathol 168 (2006) 1975-1985
78. Steffen L.S., Guyon J.R., Vogel E.D., et al. Zebrafish orthologs of human muscular dystrophy genes. BMC Genomics 8 (2007) 79
79. Bassett D.I., Bryson-Richardson R.J., Daggett D.F., Gautier P., Keenan D.G., and Currie P.D. Dystrophin is required for the formation of stable muscle attachments in the zebrafish embryo. Development 130 (2003) 5851-5860
80. Guyon J.R., Mosley A.N., Zhou Y., et al. The dystrophin associated protein complex in zebrafish. Hum Mol Genet 12 (2003) 601-615
81. Nixon S.J., Wegner J., Ferguson C., et al. Zebrafish as a model for caveolin-associated muscle disease; caveolin-3 is required for myofibril organization and muscle cell patterning. Hum Mol Genet 14 (2005) 1727-1743
82. Parsons M.J., Campos I., Hirst E.M., and Stemple D.L. Removal of dystroglycan causes severe muscular dystrophy in zebrafish embryos. Development (Cambridge, England) 129 (2002) 3505-3512
83. Cheng L., Guo X.F., Yang X.Y., et al. Delta-sarcoglycan is necessary for early heart and muscle development in zebrafish. Biochem Biophys Res Commun 344 (2006) 1290-1299
84. Guyon J.R., Mosley A.N., Jun S.J., et al. Delta-sarcoglycan is required for early zebrafish muscle organization. Exp Cell Res 304 (2005) 105-115
85. Frosk P., Greenberg C.R., Tennese A.A., et al. The most common mutation in FKRP causing limb girdle muscular dystrophy type 2I (LGMD2I) may have occurred only once and is present in Hutterites and other populations. Hum Mutat 25 (2005) 38-44
86. Kang P.B., Feener C.A., Estrella E., et al. LGMD2I in a North American population. BMC Musculoskelet Disord 8 (2007) 115
87. Poppe M., Bourke J., Eagle M., et al. Cardiac and respiratory failure in limb-girdle muscular dystrophy 2I. Ann Neurol 56 (2004) 738-741
88. Gaul C., Deschauer M., Tempelmann C., et al. Cardiac involvement in limb-girdle muscular dystrophy 2I : conventional cardiac diagnostic and cardiovascular magnetic resonance. J Neurol 253 (2006) 1317-1322
89. Mercuri E., Brockington M., Straub V., et al. Phenotypic spectrum associated with mutations in the fukutin-related protein gene. Ann Neurol 53 (2003) 537-542
90. Poppe M., Cree L., Bourke J., et al. The phenotype of limb-girdle muscular dystrophy type 2I. Neurology 60 (2003) 1246-1251
91. Sveen M.L., Schwartz M., and Vissing J. High prevalence and phenotype-genotype correlations of limb girdle muscular dystrophy type 2I in Denmark. Ann Neurol 59 (2006) 808-815
92. Walter M.C., Petersen J.A., Stucka R., et al. FKRP (826C>A) frequently causes limb-girdle muscular dystrophy in German patients. J Med Genet 41 (2004) e50
93. Darin N., Kroksmark A.K., Ahlander A.C., Moslemi A.R., Oldfors A., and Tulinius M. Inflammation and response to steroid treatment in limb-girdle muscular dystrophy 2I. Eur J Paediatr Neurol 11 (2007) 353-357
94. Godfrey C., Escolar D., Brockington M., et al. Fukutin gene mutations in steroid-responsive limb girdle muscular dystrophy. Ann Neurol 60 (2006) 603-610
95. Sveen M.L., Jeppesen T.D., Hauerslev S., Krag T.O., and Vissing J. Endurance training: an effective and safe treatment for patients with LGMD2I. Neurology 68 (2007) 59-61
96. Thornhill P., Bassett D., Lochmuller H., Bushby K., and Straub V. Developmental defects in a zebrafish model for muscular dystrophies associated with the loss of fukutin-related protein (FKRP). Brain 131 (2008) 1551-1561
97. Kurahashi H., Taniguchi M., Meno C., et al. Basement membrane fragility underlies embryonic lethality in fukutin-null mice. Neurobiol Dis 19 (2005) 208-217
98. Willer T., Prados B., Falcon-Perez J.M., et al. Targeted disruption of the Walker-Warburg syndrome gene Pomt1 in mouse results in embryonic lethality. Proc Natl Acad Sci U S A 101 (2004) 14126-14131
99. Chiyonobu T., Sasaki J., Nagai Y., et al. Effects of fukutin deficiency in the developing mouse brain. Neuromuscul Disord 15 (2005) 416-426
100. Takeda S., Kondo M., Sasaki J., et al. Fukutin is required for maintenance of muscle integrity, cortical histiogenesis and normal eye development. Hum Mol Genet 12 (2003) 1449-1459
101. Michele D.E., Barresi R., Kanagawa M., et al. Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies. Nature 418 (2002) 417-422
102. Barresi R., Michele D.E., Kanagawa M., et al. LARGE can functionally bypass alpha-dystroglycan glycosylation defects in distinct congenital muscular dystrophies. Nat Med 10 (2004) 696-703
103. Roberds S.L., Leturcq F., Allamand V., et al. Missense mutations in the adhalin gene linked to autosomal recessive muscular dystrophy. Cell 78 (1994) 625-633